World Markets

Sarepta to buy gene therapy developer Myonexus for $165 mln

Feb 27 (Reuters) - Sarepta Therapeutics Inc said on Wednesday it exercised its option to buy privately held gene therapy maker Myonexus Therapeutics Inc for $165 million.

Sarepta and Myonexus had entered into an exclusive partnership last May to develop Myonexus' five gene therapy candidates for treating different forms of Limb-girdle muscular dystrophy, a group of muscle-wasting disorders.

As part of the deal, Sarepta had an exclusive option to acquire Myonexus.


The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

In This Story

SRPT

Other Topics

Stocks

Reuters

Reuters, the news and media division of Thomson Reuters, is the world’s largest international multimedia news provider reaching more than one billion people every day. Reuters provides trusted business, financial, national, and international news to professionals via Thomson Reuters desktops, the world's media organizations, and directly to consumers at Reuters.com and via Reuters TV.

Learn More